Alkermes

Quote
















































anonymous said:
I got a call about an Alkermes opening in my area and the comp package does sound good especially the target bonus. My concerns which I am not sure can be answered in an interview revolve around quotas and the new drug. I keep thinking about how many of my friends over there that have struggled to make their quotas quarter after quarter which says their people at the top may not be reasonable. My second concern is this new MDD drug that they are banking on may not get approved due to the fact they filed with only one positive phase 3 study because the other two phase 3 studies failed to meet the primary endpoints. It usually takes two positive Phase 3 outcomes to appease the FDA. Just today I read that because the drug is made up of two opioid modulators it could end up being scheduled which then means no samples. This would be a huge competitive disadvantage in the MDD market. You can google ALKs 5461 and read about this stuff. I am not sure what I am going to do yet but thought folks would like to read what I have uncovered
Click to expand...


I called this about the Alkermes drug Alks 5461 in my post on February 25th. Alkermes is all smoke and mirrors. At least I heard encouraging news at our meeting last week in Vegas. I am going to sit tight.
 






The same thing will happen here with our new drug candidate. The FDA is hammering down on all pharma companies submitting NDAs in markets where there are already lower cost alternatives. If you cant show any relevant clinically statistical significance, your new product candidate will just get shoved to the back of the line. FDA will just refuse to look at your drug unless you provide more studies, spend more money in R&D which all leads to just give up!!!
 


































































Top Bottom
Back
Quote